We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regulators Seek to Reduce ‘Residual Uncertainty’ With Drug Development
Regulators Seek to Reduce ‘Residual Uncertainty’ With Drug Development
October 8, 2010
As safety continues to be a paramount FDA concern, regulators are looking to minimize “residual uncertainty” associated with drugs, according to a former agency official.